At the 2024 European Respiratory Society (ERS) Annual Meeting, Chinese scholars proposed a new goal for the treatment of asthma "remission", aiming to help asthma patients achieve long-term remission through the early use of biologics (such as dupilumab). This treatment strategy not only focuses on controlling symptoms, but also strives to reduce airway remodeling and lung function decline through immunological intervention in the early stages of the disease, thereby reducing long-term damage to the respiratory system.
Studies have shown that biologics such as dupilumab have achieved significant results in improving the airway structure and lung function of asthma patients, especially for patients at risk of airway remodeling. This treatment effect has important clinical significance. By intervening with biologics in the early stages of asthma, it is expected to delay or avoid irreversible changes in the airways and significantly improve the quality of life of patients.
